ADMINISTRATION
*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
Flexible administration with OXLUMO® (lumasiran)—at home or in the office
Some patients may qualify for at-home injections, administered by a healthcare professional, if covered by insurance.
After 4 initial monthly doses, patients ≥10 kg can receive OXLUMO quarterly1
Convenient quarterly or monthly (for patients <10 kg) ongoing administration by a healthcare professional helps ensure correct dosing and long-term adherence.1
3 starting doses: 3 mg/kg administered monthly
Month 1
Month 2
Month 3
Ongoing dosing: 3 mg/kg administered quarterly, with the first ongoing dose administered 1 month after the last starting dose
Month 4
Month 5
Month 6
Month 7
Ongoing quarterly dosing continues past month 7
3 starting doses: 6 mg/kg administered monthly
Month 1
Month 2
Month 3
Ongoing dosing: 6 mg/kg administered quarterly, with the first ongoing dose administered 1 month after the last starting dose
Month 4
Month 5
Month 6
Month 7
Ongoing quarterly dosing continues past month 7
3 starting doses: 6 mg/kg administered monthly
Month 1
Month 2
Month 3
Ongoing dosing: 3 mg/kg administered monthly, with the first ongoing dose administered 1 month after the last starting dose
Month 4
Month 5
Month 6
Month 7
Ongoing monthly dosing continues past month 7
WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?
Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.
There’s more to learn about OXLUMO
When you sign up, we will keep you informed with updates and resources.
Alnylam Assist® provides support services for patients throughout their treatment with OXLUMO
Alnylam Assist® includes patient services in 4 key areas, including understanding insurance benefits and financial assistance options for eligible patients,* helping ensure access to therapy, and providing PH1 disease education.
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
1. OXLUMO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.